Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type

By sjmartinez • November 12, 2023

Alexis AF, Silverberg JI, Rice ZP, Armstrong AW, Desai SR, Fonacier L, Kabashima K, Biswas P, Cella RR, Chan GL, Levenberg M. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type. Ann Allergy Asthma Immunol. 2023 Nov 8:S1081-1206(23)01394-7. doi: 10.1016/j.anai.2023.11.002. Epub ahead of print. PMID: 37949351.

Tags: abrocitinib, atopic eczema, Clinical Trial, Dermatology, Ethnicity, Publications, Race

Assessing GPT-4’s Diagnostic Accuracy with Darker Skin Tones: Underperformance and Implications

Akuffo-Addo E, Samman L, Munawar L, Akbik M, Kokikian N, Wescott R, Wu JJ. Assessing GPT-4's Diagnostic Accuracy with Darker Skin Tones: Underperformance and Implications.[...]

Engaging industry effectively and ethically in artificial intelligence from the Augmented Artificial Intelligence Committee Standards Workgroup

Lee I, Aninos A, Lester J, Rotemberg V, Schlessinger DI, Weed J, Wongvibulsin S, Daneshjou R. Engaging industry effectively and ethically in artificial intelligence from[...]

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers

Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford[...]